PhD ’88, University of California, San Francisco
An eminent leader in cancer genetics, Tyler Jacks is founding director of MIT’s Koch Institute for Integrative Cancer Research and an investigator of the Howard Hughes Medical Institute.
Known for his pioneering work in creating sophisticated, genetically engineered models of human cancer, Jacks has received numerous awards for his research, including the 2015 Killian Award, the highest honor MIT grants to its faculty members.
A member of the National Academies of Science and Medicine, Jacks has served as president of the American Association for Cancer Research, chair of the National Cancer Advisory Board, and co-chair of the Blue Ribbon Panel for the National Cancer Institute’s Cancer Moonshot initiative.
A graduate of Harvard College, he has collaborated frequently with Harvard faculty colleagues and has mentored many Harvard students and postdoctoral fellows over his 26 years on the MIT faculty. He has also co-led the Bridge Project, which supports collaborative research between MIT and the Dana-Farber/Harvard Cancer Center.
Jacks is a current or past member of numerous boards and advisory boards of universities, foundations, government organizations, and life-sciences companies. He is also the cofounder of Dragonfly Therapeutics, launched in 2015 with a Harvard College suitemate.
“My father, also a Harvard College graduate (Class of ’43), was fond of saying that the country is only as great as its great institutions. Given the challenges that face higher education today, my fundamental interest in serving on the Board of Overseers is ensuring that Harvard remains in position to lead through education, research, public policy, and public discourse.”